Objective-To establish if urinary excretion rates of the collagen crosslinks pyridinoline and deoxypyridinoline, which are known to be elevated in established rheumatoid arthritis (RA), are useful markers of bone loss in this disease. Methods-Eight hour urine collections on all patients and 52 controls were performed, and the rates of pyridinoline and deoxypyridinoline excretion were measured. Bone mineral density (BMD), by dual energy x-ray absorption, and full laboratory and clinical assessments were performed. Results-The rates of excretion of pyridinoline and deoxypyridinoline were significantly increased in patients compared with controls (p < 0.001). Pyridinoline excretion was associated with increased disease activity (ESR/CRP) but not disability (HAQ score/Functional Grade), and correlated with BMD loss at the femoral neck (p < 0.01).
the femoral neck (p < 0.01).
Conclusion-The excretion of collagen crosslinks may be useful as markers of bone and cartilage turnover in patients with RA. measurement of the skeleton quick and accurate using a low dose of radiation. '7 Despite the many advantages of DXA there is still a need for a sensitive and specific marker which is able to identify patients who are 'fast bone losers' and to provide rapid indication of any response to therapy. Measurement of the urinary excretion of the collagen crosslinks pyridinoline and deoxypyridinoline has been proposed as such.'8-20 Deoxypyridinoline is bone specific, being found in type I collagen only.2' By contrast pyridinoline is found both in skeletal and vascular connective tissue, but quantitatively is the major crosslinking compound in bone. Following mature collagen degradation, these crosslinks are released in free of peptide forms and are excreted unchanged in urine, where they can be accurately quantified using HPLC.22 23 Patients also completed a questionnaire detailing calcium intake, smoking habits and 23 Briefly, 250 ml aliquots of urine were hydrolysed at 11 0°C for 18 hours in equal volumes of 6 molar hydrochloric acid. This converts the peptide bound crosslinks to their free forms. The resulting hydrolysates were fractionated by CFI cellulose column chromatography to remove interfering fluorescent compounds. The crosslinks were separated and quantified by reverse-phase HPLC with fluorescent spectroscopy using heptafluorobutyric acid as the ion pairing agent. Duplicate samples were analysed for each patient and from this eight hour urinary excretion rates were calculated with values expressed in nmol per eight hours. The intra assay variation was <10% for pyridinoline and <15% for deoxypyridinoline.
T tests and product moment correlation coefficients were used to examine the association between pairs of factors, but as several questionnaire and qualitative factors could have potentially influenced a patient's BMD, analysis of covariance was finally used to examine the relative significance of each factor. Where necessary, a backward elimination of the least significant factors was performed to arrive at the collection of factors having a significant effect on bone loss.
Results
The demographic and descriptive details of the 62 patients studied are shown in Urinary eight hour crosslink excretion rates were significantly increased in patients with early RA in all patient groups, except postmenopausal women for pyridinoline and premenopausal women for deoxypyridinoline (table 2a, b). Comparing crosslink excretion with the change in BMD, premenopausal women lost bone more rapidly than postmenopausal patients [mean (SD) -1 8 (3 6) and -2 8 (6 2) v -0 1 (4 3) and -2 1 (6) (NS) spine and femoral neck respectively]. This was despite crosslink excretion rates being elevated in the postmenopausal women. The ratio to pyridinoline to deoxypyridinoline showed a significant difference between postmenopausal patients and controls (table 3). Eight patients took oral steroids, two each in the pre-and postmenopausal groups and four men. Only two patients took HRT.
To assess the role of disability and disease activity in determining the rate of bone loss, the patients were sub-divided on the basis of their mean acute phase and functional ability scores. Active disease was taken as mean CRP 20 mg/dl or ESR > 30 and significant disability as HAQ > 8 and FG > 2. These were arbitrarily assigned before any statistical analysis. Disease activity, as assessed by mean CRP, was significantly associated with bone loss and increased pyridinoline excretion (table 4) . Analysis using ESR produced results of similar significance. The HAQ score, as a measure of disability, had no significant effect on either bone loss or crosslink excretion (data not shown). Using an analysis of covariance for all factors confirmed the association of disease activity with crosslink excretion rates and bone loss. Although there was no correlation between deoxypyridinoline excretion and changes at the femoral neck or lumbar spine, there was an association between BMD loss at the femoral neck and pyridinoline excretion (p < 0-01).
Discussion
This study demonstrated that urinary pyridinoline excretion was increased in patients with RA compared with controls and was significantly associated with disease activity, consistent with previous studies.'9 20 For deoxypyridinoline (the more bone specific crosslink), levels did not correlate with activity in line with previous studies.'9 20 Previous studies examining patients in the chronic phase of RA cross sectionally have demonstrated an association between BMD loss and disability.9 14 28 29 In our study this association was not found despite using HAQ as a more sensitive index of functional loss. There was, however, a significant correlation between BMD loss and CRP with similar findings for ESR (table 4) . The separation between disease activity and disability scores in these patients was possibly a consequence of the minimal joint damage of patients studied at this stage of their disease.
Substantial axial bone loss occurring in premenopausal women was observed with losses of greater than 1 0% over one year in some nonsteroid treated patients. Bone histomorphometry in RA patients has shown that trabecular thinning occurs in premenopausal women, and also men, whereas trabecular breaks can occur in postmenopausal women. 30 The former may be reversible but the latter are not. As BMD loss is associated with CRP, this might suggest that early and complete suppression of the acute phase response is important in these patients. Longitudinal data will be required to properly address this question.
DXA scans remain the gold standard for measuring bone loss. Their inherent disadvantage is that they are long term measures of outcome that are insensitive to short term change. There is a clinical need for markers which are capable of determining changes in bone turnover, allowing rapid assessment of response to therapy. In osteoporotic patients, excretion of deoxypyridinoline may have such a role and has been found to correlate with radiostrontium measurements of bone resorption. 22 23 We, however, found no association between the excretion of this crosslink and BMD change over one year, whereas pyridinoline excretion was significantly associated with BMD loss at the femoral neck (p < 0-01). It is possible therefore that the excretion of pyridinoline from intra articular, juxta articular and axial sites explains this correlation with bone loss in these patients with early RA.
This study has shown that a single estimation of urinary pyridinoline excretion in patients with early RA correlated-significantly with bone loss at the femoral neck. This could become a useful predictive test, especially as there is now evidence that a spot early morning urine specimen may provide the same information.3" 12 Cooper C. Reviews of UK data on the rheumatic diseases. 
